Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Compare top high-yield ETFs by income potential and durability to select funds that optimize retirement cash flow and resilience.
27,330 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Amundi, Europe's biggest asset manager, launches a UCITS-compliant Solana fund in partnership with SPiko Finance, mar...
New fiscal data show tariffs only generating revenue are not near enough to cover debt service, even as deficits wide...
Institutional landlords are stepping up the sale of single-family rentals as the ROAD Act takes effect. Early data sh...
Is SoFi Technologies stock your path to wealth? This guide weighs growth potential, risks, and practical steps to hel...
States are unlocking church land for housing through by-right rules, aiming to speed up construction and boost afford...
A coalition of 37 European banks plans a euro-denominated stablecoin to challenge dollar rails, targeting wholesale c...
Despite a chorus of buy ratings on Shopify, a dissenting view flags limited upside as AI tools and monetization effor...
Alphabet's AI ambitions are under scrutiny as cloud momentum and big-capex raise the stakes. Here’s what investors sh...
Morgan Stanley reports record revenue for 2025 and a solid Q4, but shares fall as liquidity constraints in private ma...
A New York rally billed as a discussion on the economy devolved into tangents about toiletries and voter rules, under...
PayPal trades around $42 as Wall Street reassesses fintech bets. Despite steady cash flow and a substantial buyback, ...